Log in to search using one of your social media accounts:

 

Calvin ’s gift: Second opinion provides answers and hope
It’s not often that parents breathe a sigh of relief when their child is diagnosed with a chronic, potentially debilitating condition. But that sense of peace is just what Paula and Scott Hurd felt when they were told that their son, Calvin, had a rare movement disorder. “We were so happy to finally understand what was happening,” says Paula. Slipping away The search for answers had begun several years earlier, when Calvin started limping. At first, his family thought he had simply tripped over something and injured himself. But when he didn’t improve, they took him to the doctor. A series of appoi...
Source: Thrive, Children's Hospital Boston - September 13, 2017 Category: Pediatrics Authors: Jessica Cerretani Tags: Diseases & Conditions Our Patients’ Stories cerebral palsy Cerebral Palsy Program Dr. Benjamin Shore Dr. David Coulter dystonia Second opinion Source Type: news

Acorda Receives Refusal to File Letter from FDA for Inbrija (CVT-301, levodopa inhalation powder) New Drug Application
ARDSLEY, N.Y.--(BUSINESS WIRE)--August 29, 2017 -- Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - August 29, 2017 Category: Drugs & Pharmacology Source Type: news

Diabetes drug may be helpful for Parkinson's disease
Conclusion This research shows some interesting early findings, though the magnitude of effect was very small compared to the improvements in symptoms with current dopaminergic drugs. The study was well conducted but did have some limitations: The number of people taking part was quite small. This may have meant it was hard to detect any other benefits or harms of taking the drug other than the effects on motor scores. The period of time people were given the drug and followed up meant that longer-term effects could not be measured. The benefit of the drug observed so far might not be big enough to make a difference ...
Source: NHS News Feed - August 4, 2017 Category: Consumer Health News Tags: Neurology Source Type: news

FDA Drug Safety Communication: Ongoing Safety Review of Stalevo (entacapone/carbidopa/levodopa) and possible development of Prostate Cancer
[03-31-2010] The U.S. Food and Drug Administration (FDA) is evaluating clinical trial data that may suggest that patients taking Stalevo, a Parkinson's disease medication, may be at an increased risk for developing prostate cancer. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 3, 2017 Category: Drugs & Pharmacology Source Type: news

Acorda Submits New Drug Application to U.S. Food and Drug Administration for Inbrija (CVT-301, Levodopa Inhalation Powder)
ARDSLEY, N.Y.--(BUSINESS WIRE) June 29, 2017 -- Acorda Therapeutics, Inc. (NASDAQ: ACOR) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Inbrija (CVT-301, levodopa inhalation powder). Acorda is... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - June 29, 2017 Category: Drugs & Pharmacology Source Type: news

Working Toward a World Without Parkinson ’s Disease
John L. Lehr is chief executive officer of the Parkinson’s Foundation. By John L. LehrNEW YORK, Jun 27 2017 (IPS)As one expert recently noted, if Parkinson’s were an infectious disease, we would call it an epidemic. Worldwide, 10 million people live with Parkinson’s disease, a number expected to double in the next 20 years. While there is no cure for Parkinson’s and no proven way to slow its progression, there is new reason to hope for a world without Parkinson’s. John L. LehrThe varied symptoms of Parkinson’s – including tremor, slowness, fatigue and cognitive difficulties –...
Source: IPS Inter Press Service - Health - June 27, 2017 Category: International Medicine & Public Health Authors: John Lehr Tags: Development & Aid Featured Global Headlines Health TerraViva United Nations Source Type: news

Quest to prevent Macular degeneration continues with UA researcher's $1.7m NIH grant
(University of Arizona Health Sciences) After showing that individuals who take levodopa, or l-dopa, for movement disorders such as Parkinson's disease are protected from developing macular degeneration, University of Arizona researcher Brian S. McKay, PhD, is taking the next step in his quest to prevent the blinding eye disease, thanks to a $1.7 million R01 grant from the National Eye Institute of the National Institutes of Health. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 26, 2017 Category: International Medicine & Public Health Source Type: news

Extended-Release Amantadine Effective for Dyskinesia in PD Extended-Release Amantadine Effective for Dyskinesia in PD
A phase 3 study shows a once-daily formulation of amantadine is superior to placebo in reducing severity and duration of levodopa-induced dyskinesia in patients with Parkinson's.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 21, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Drug reduces dyskinesia, 'off' times in Parkinson's patients
(Reuters Health) - An experimental extended-release version of the drug amantadine can reduce the duration of the involuntary dancing-like movements seen in people whose long-term use of levodopa has kept their Parkinson ’s disease under control. (Source: Reuters: Health)
Source: Reuters: Health - June 12, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Inhaled Levodopa Improves Motor Symptoms in Parkinson's Inhaled Levodopa Improves Motor Symptoms in Parkinson's
Phase 3 study results showed that inhaled formulation of levodopa outperformed placebo at 12 weeks, reducing'off'periods and improving motor scores in patients with Parkinson's disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 9, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Inhaled Levodopa Cuts Motor Symptoms in Parkinson's'Off' Episodes
(MedPage Today) -- Drugmaker Acorda to seek FDA approval shortly (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - June 8, 2017 Category: Primary Care Source Type: news

Novel Parkinson Therapies Highlighted at AAN Meeting
(MedPage Today) -- Early results with gene therapy, new carbidopa-levodopa formulation featured (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - April 27, 2017 Category: Geriatrics Source Type: news

150-Year-Old Drug May Help Parkinson's Patients
Study finds apomorphine cuts the time until levodopa kicks in for those with advanced disease (Source: WebMD Health)
Source: WebMD Health - April 22, 2017 Category: Consumer Health News Source Type: news

Acorda plans NDA for inhaled Parkinson ’ s drug after touting long-term safety data
Acorda Therapeutics (NSDQ:ACOR) touted data from 2 ongoing, long-term safety studies of its inhaled Parkinson’s therapy. The trials showed no difference in pulmonary function between the group receiving CVT-301, the inhaled formulation of Parkinson’s drug levodopa, and the control group. The investigational drug is being studied as a therapy for people with Parkinson’s disease experiencing “off” periods, or a re-emergence of symptoms. The Ardsley, N.Y.-based company said the 12-month safety results are consistent with data from Phase IIb and III clinical evaluations. Get the full sto...
Source: Mass Device - March 30, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Neurological Pharmaceuticals Respiratory Wall Street Beat Acorda Therapeutics Source Type: news

New Parkinson's Drug Xadago Approved
WEDNESDAY, March 22, 2017 -- Xadago (safinamide) tablets have been approved by the U.S. Food and Drug Administration as an add-on drug to treat Parkinson's patients who take levodopa or carbidopa but have instances of increased symptoms anyway, a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 22, 2017 Category: Journals (General) Source Type: news

FDA approves drug to treat Parkinson's disease
The U.S. Food and Drug Administration has approved Xadago (safinamide) tablets as an add-on treatment for patients with Parkinson's disease who are currently taking levodopa/carbidopa and... (Source: Parkinson's Disease News From Medical News Today)
Source: Parkinson's Disease News From Medical News Today - March 22, 2017 Category: Neurology Tags: Parkinson's Disease Source Type: news

FDA OKs Parkinson's Add-On Drug, Xadago (Safinamide)
WEDNESDAY, March 22, 2017 -- The U.S. Food and Drug Administration has approved a new drug for Parkinson's disease. Xadago (safinamide) pills were given the green light as an add-on treatment for people taking levodopa/carbidopa and experiencing... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 22, 2017 Category: Journals (General) Source Type: news

FDA approves drug to treat Parkinson's disease
The U.S. Food and Drug Administration has approved Xadago (safinamide) tablets as an add-on treatment for patients with Parkinson's disease who are currently taking levodopa/carbidopa and experiencing "off" episodes. An "off" episode is a time when a patient’s medications are not working well, causing an increase in Parkinson's symptoms, such as tremor and difficulty walking. (Source: World Pharma News)
Source: World Pharma News - March 22, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

FDA Okays Safinamide (Xadago) for Parkinson's Disease FDA Okays Safinamide (Xadago) for Parkinson's Disease
Safinamide is approved as adjunctive treatment for patients with Parkinson's disease who experience'off'episodes while taking levodopa/carbidopa.FDA Approvals (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 21, 2017 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news

Troubled MAOI for PD'Off' Episodes Nabs FDA Approval
(MedPage Today) -- Safinamide had rocky regulatory road as levodopa/carbidopa add-on (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - March 21, 2017 Category: Geriatrics Source Type: news

FDA Approves Xadago (safinamide) as an Add-On Treatment for Patients with Parkinson ’s Disease
March 21, 2017 -- The U.S. Food and Drug Administration today approved Xadago (safinamide) tablets as an add-on treatment for patients with Parkinson ’s disease who are currently taking levodopa/carbidopa and experiencing “off” episodes. An... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 21, 2017 Category: Drugs & Pharmacology Source Type: news

FDA approves Newron's drug as add-on therapy for Parkinson's
(Reuters) - Newron Pharmaceuticals SpA said on Tuesday the U.S. Food and Drug Administration approved its Parkinson's disease treatment Xadago as an add-on therapy to levodopa, a drug widely used to treat the disease. (Source: Reuters: Health)
Source: Reuters: Health - March 21, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA approves drug to treat Parkinson ’s disease
The U.S. Food and Drug Administration today approved Xadago (safinamide) tablets as an add-on treatment for patients with Parkinson ’s disease who are currently taking levodopa/carbidopa and experiencing “off” episodes. An “off” episode is a time when a patient’s medications are not working well, causing an increase in Parkinson’s symptoms, such as tremor and difficulty walking. (Source: Food and Drug Administration)
Source: Food and Drug Administration - March 21, 2017 Category: American Health Source Type: news

FDA approves drug to treat Parkinson ’ s disease
The U.S. Food and Drug Administration today approved Xadago (safinamide) tablets as an add-on treatment for patients with Parkinson ’ s disease who are currently taking levodopa/carbidopa and experiencing “ off ” episodes. An “ off ” episode is a time when a patient ’ s medications are not working well, causing an increase in Parkinson ’ s symptoms, such as tremor and difficulty walking. (Source: Food and Drug Administration)
Source: Food and Drug Administration - March 21, 2017 Category: American Health Source Type: news

Lodosyn (Carbidopa) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 7, 2017 Category: Drugs & Pharmacology Source Type: news

Positive Top-Line Results for Inhalable Parkinson's Treatment Positive Top-Line Results for Inhalable Parkinson's Treatment
The phase 3 SPAN-PD trial of CVT-301, an inhalable formulation of levodopa, met its primary endpoint of improved motor impairment vs placebo at 12 weeks, according to its manufacturer.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - February 9, 2017 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Acorda ’ s inhaled Parkinson ’ s drug meets primary endpoint in Phase III trial
Acorda Therapeutics (NSDQ:ACOR) said today that the phase III clinical trial evaluating its inhaled formulation of Parkinson’s drug levodopa met its primary endpoint. The drug was studied as a therapy for people with Parkinson’s disease experiencing “off” periods, or a re-emergence of symptoms. The randomized phase III trial enrolled 339 patients to evaluate the efficacy and safety of CVT-301 compared with a placebo in patients with Parkinson’s who experience motor fluctuations. Study participants self-administered the therapy up to 5 times per day for 12 weeks. Get the full story at our siste...
Source: Mass Device - February 9, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Respiratory Wall Street Beat Acorda Therapeutics Source Type: news

Managing Parkinson's Disease During Ramadan Managing Parkinson's Disease During Ramadan
A new review highlights the perils of missing doses of the short-acting drug levodopa during fasting among Muslim patients with PD and advises on alternatives and options.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - January 10, 2017 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Opicapone Helps Control Motor Fluctuations in Parkinson's Opicapone Helps Control Motor Fluctuations in Parkinson's
A new study shows adding this once-daily COMT inhibitor to levodopa therapy had significant therapeutic benefits and was well tolerated and easy to dose.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - January 6, 2017 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Adamas Announces U.S. FDA Acceptance of ADS-5102 New Drug Application for the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinson's Disease
EMERYVILLE, Calif., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ADS-5102 (amantadine... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - January 6, 2017 Category: Drugs & Pharmacology Source Type: news

Experimental Parkinson's drug may combat movement difficulties
Alan Mozes, HealthDay News Parkinson's disease patients may achieve better, more reliable motor control by taking the experimental drug opicapone with the standard medication levodopa. (Source: Health News - UPI.com)
Source: Health News - UPI.com - January 4, 2017 Category: Consumer Health News Source Type: news

New Parkinson's Drug May Combat Movement Difficulties
TUESDAY, Jan. 3, 2017 -- New research suggests that people with Parkinson's disease may achieve better and more reliable motor control by taking an experimental drug called opicapone alongside the standard medication levodopa. A study of several... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 3, 2017 Category: Journals (General) Source Type: news

Sinemet CR (Carbidopa-Levodopa Sustained Release) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 15, 2016 Category: Drugs & Pharmacology Source Type: news

Intec Pharma inks deal with Michael J. Fox Foundation for patient recruitment
Intec Pharma (NSDQ:NTEC) said today that it inked a deal with the Michael J. Fox Foundation for Parkinson’s Research to support the biopharmaceutical company’s patient recruitment and retention for its pivotal phase III trial. The study will evaluate Intec Pharma’s lead candidate, the “accordion pill” carbidopa/levodopa (AP-CD/LD), as a treatment for patients with advanced Parkinson’s disease. The Israel-based company began enrolling patients in its phase III trial in April 2016. In 2013, the Michael J. Fox foundation supported the company with a $705,000 grant to fund a precli...
Source: Mass Device - November 28, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Neurological Pharmaceuticals Wall Street Beat Intec Pharma Source Type: news

Once-Daily Oral Med May Reduce Levodopa-Induced Dyskinesia Once-Daily Oral Med May Reduce Levodopa-Induced Dyskinesia
A once-daily extended-release medication may rapidly improve levodopa-induced dyskinesia, a major clinical issue in patients with Parkinson's disease, new research shows.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 6, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Sinemet (Carbidopa-Levodopa) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 1, 2016 Category: Drugs & Pharmacology Source Type: news

Why brain neurons in Parkinson's disease stop benefiting from levodopa
Though the drug levodopa can dramatically improve Parkinson's disease symptoms, within five years one-half of the patients using L-DOPA develop an irreversible condition -- involuntary repetitive, rapid and jerky movements. UAB researchers have uncovered an essential mechanism of long-term memory for L-DOPA-induced-dyskinesia: widespread reorganization of DNA methylation, and this may be a therapeutic target to prevent or reverse dyskinesia. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 28, 2016 Category: Science Source Type: news

Why brain neurons in Parkinson's disease stop benefiting from levodopa
( University of Alabama at Birmingham ) Though the drug levodopa can dramatically improve Parkinson's disease symptoms, within five years one-half of the patients using L-DOPA develop an irreversible condition -- involuntary repetitive, rapid and jerky movements. UAB researchers have uncovered an essential mechanism of long-term memory for L-DOPA-induced-dyskinesia: widespread reorganization of DNA methylation, and this may be a therapeutic target to prevent or reverse dyskinesia. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 28, 2016 Category: Global & Universal Source Type: news

Rytary (Carbidopa and Levodopa Capsules) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 18, 2016 Category: Drugs & Pharmacology Source Type: news

NeuroDerm Announces Additions to Management Team
REHOVOT, Israel, July 06, 2016 -- (Healthcare Sales & Marketing Network) -- NeuroDerm Ltd. (NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today announced the appointments of Tami Yardeni as Chie... Biopharmaceuticals, Devices, Neurology, PersonnelNeuroDerm, ND0612H, Parkinson’s disease, Levodopa, Carbidopa (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 6, 2016 Category: Pharmaceuticals Source Type: news

Continuous L-Dopa Enteric Infusion Relieves RLS SymptomsContinuous L-Dopa Enteric Infusion Relieves RLS Symptoms
Continuous enteric infusion of levodopa markedly relieved symptoms of restless legs syndrome and improved quality of life in a patient with contraindications to alternative drugs, a case report shows. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - June 24, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Parkinson’s disease impairs masticatory function
Clinical Oral Investigations pp 1-8First online: 13 June 2016 Abstract ObjectiveTo evaluate masticatory function in individuals with Parkinson’s disease (PD) during levodopa “on” period using new removable dental prosthesis. Materials and methodsA total of 34 elderly individuals with PD (n = 17, mean age = 69.41 ± 4.65 years) or without PD (n = 17, mean age = 70.71 ± 4.65 years) were recruited for this study. Participants received new complete dentures and/or removable parti...
Source: Dental Technology Blog - June 17, 2016 Category: Dentistry Source Type: news

Parkinson ’s disease impairs masticatory function
Conclusion PD patients have impaired masticatory function during levodopa “on” periods compared to controls. Clinical relevance Knowledge that PD is associated with impaired masticatory function is important to dental professionals in decision making related to prosthetics and general dental treatment. (Source: Dental Technology Blog)
Source: Dental Technology Blog - June 17, 2016 Category: Dentistry Source Type: news

Extended-Release Amantadine May Improve Levodopa Dyskinesia Control
VANCOUVER — An extended-release amantadine formulation reduced levodopa-induced dyskinesia in a phase III Parkinson’s disease trial from the drug’s developer, Adamas Pharmaceuticals. (Source: Caring for the Ages)
Source: Caring for the Ages - May 28, 2016 Category: Health Management Authors: M. Alexander Otto Source Type: news

Zambon Launches Xadago(R) (Safinamide) in the U.K. for Patients with Mid- to Late-Stage Parkinson’s Disease
Zambon today announces the availability in the U.K. of Xadago® (safinamide) for the treatment of adult patients with idiopathic Parkinson’s disease (PD) as an add-on therapy to a stable dose of Levodopa (L-dopa) alone or in combination with other Parki... Biopharmaceuticals, Neurology, Product LaunchNewron Pharmaceuticals, Zambon, Xadago, Parkinson’s disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 23, 2016 Category: Pharmaceuticals Source Type: news

Parcopa (Carbidopa and Levodopa Extended-release Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 13, 2016 Category: Drugs & Pharmacology Source Type: news

Extended-release amantadine may improve levodopa dyskinesia control
VANCOUVER – An extended-release amantadine formulation reduced levodopa-induced dyskinesia in a phase III Parkinson’s disease trial from the drug’s developer, Adamas Pharmaceuticals. Amantadine... (Source: Clinical Neurology News)
Source: Clinical Neurology News - April 21, 2016 Category: Neurology Source Type: news

Extended-release amantadine may improve levodopa dyskinesia control
VANCOUVER – An extended-release amantadine formulation reduced levodopa-induced dyskinesia in a phase III Parkinson’s disease trial from the drug’s developer, Adamas Pharmaceuticals. Amantadine... (Source: Family Practice News)
Source: Family Practice News - April 21, 2016 Category: Primary Care Source Type: news

Intec Pharma enrols first patient in phase III trial of AP-CDLD for advanced Parkinson's
Intec Pharma has enrolled the first patient in the US under its phase III clinical trial for Accordion Pill Carbidopa/Levodopa (AP-CDLD) for treatment of patients with advanced Parkinson's disease. (Source: Drug Development Technology)
Source: Drug Development Technology - April 4, 2016 Category: Pharmaceuticals Source Type: news

FDA Drug Safety Communication: Ongoing Safety Review of Stalevo and possible increased cardiovascular risk
[08-20-2010] The U.S. Food and Drug Administration (FDA) is evaluating clinical trial data that suggest patients taking Stalevo (a combination of carbidopa/levodopa and entacapone) may be at an increased risk for cardiovascular events (heart attack, stroke, and cardiovascular death) compared to those taking carbidopa/levodopa (sold as the combination product, Sinemet). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 2, 2016 Category: Drugs & Pharmacology Source Type: news